| scholarly article | Q13442814 |
| P50 | author | Peter Hillmen | Q48086375 |
| Jaroslaw P. Maciejewski | Q89912865 | ||
| P2093 | author name string | Neal S Young | |
| Hubert Schrezenmeier | |||
| Jörg Schubert | |||
| Luke Coyle | |||
| Monica Bessler | |||
| Carlos de Castro | |||
| Elisabetta Antonioli | |||
| Robert A Brodsky | |||
| Antonio M Risitano | |||
| Anna Gaya | |||
| Russell P Rother | |||
| Chieh-Lin Fu | |||
| Henk-André Kroon | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| paroxysmal nocturnal hemoglobinuria | Q1479494 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1840-1847 | |
| P577 | publication date | 2007-11-30 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria | |
| P478 | volume | 111 |
| Q40093163 | A Case of Fulminant Meningococcemia: It Is All in the Complement. |
| Q98947238 | A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy |
| Q90509576 | A Randomized, Double-Blind, Single-Dose, Three-Arm, Parallel Group Study to Determine Pharmacokinetic Similarity of ABP 959 and Eculizumab (Soliris® ) in Healthy Male Subjects |
| Q40722397 | A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America |
| Q33602746 | A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model |
| Q35536766 | A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data |
| Q64115326 | Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q49253055 | Acute myeloid leukemia and fatal Scedosporium prolificans sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report |
| Q46852478 | Adapting Practice in the Face of New Data |
| Q36366577 | Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria |
| Q37185654 | An Inhibitor of the Alternative Pathway of Complement in Saliva of New World Anopheline Mosquitoes. |
| Q37724607 | Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going |
| Q93147350 | Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT |
| Q37336472 | Anti-inflammatory interventions-what has worked, not worked, and what may work in the future |
| Q89093231 | Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q33419128 | Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome |
| Q33595396 | Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis |
| Q36315497 | Applying complement therapeutics to rare diseases. |
| Q50433937 | Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria |
| Q39429501 | Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab |
| Q40064380 | Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report |
| Q33855860 | Autocrine effects of tumor-derived complement. |
| Q33558763 | Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry |
| Q38514894 | Biologic agents in the treatment of glomerulonephritides |
| Q37235669 | Blood consult: paroxysmal nocturnal hemoglobinuria and its complications |
| Q61796443 | C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro |
| Q39681633 | Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry |
| Q84192839 | Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena |
| Q48287099 | Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry |
| Q34492818 | Clinical management of paroxysmal nocturnal haemoglobinuria in pregnancy: three case reports |
| Q86701446 | Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry |
| Q50050284 | Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. |
| Q35953532 | Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. |
| Q33380163 | Complement and the atypical hemolytic uremic syndrome in children. |
| Q34603645 | Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria |
| Q26740491 | Complement in Lupus Nephritis: New Perspectives |
| Q35252156 | Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape |
| Q38609238 | Complement inhibition as potential new therapy for antibody-mediated rejection. |
| Q34866828 | Complement inhibition to treat myocardial infarction? |
| Q33385154 | Complement inhibitor eculizumab in atypical hemolytic uremic syndrome |
| Q38614302 | Complement, a target for therapy in inflammatory and degenerative diseases. |
| Q90029318 | Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria |
| Q39142842 | Complementopathies |
| Q39566121 | Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria |
| Q35032418 | Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria |
| Q54740302 | Deep vein thrombosis in association with acute intravascular haemolysis in glucose-6-phosphate dehydrogenase deficiency: a unique case. |
| Q64039251 | Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III |
| Q92238529 | Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species |
| Q37580829 | Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. |
| Q99563541 | Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH) |
| Q90394623 | Diagnosis of paroxysmal nocturnal hemoglobinuria with flowcytometry panels including CD157: Data from the real world |
| Q92404937 | Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients |
| Q33430320 | Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome |
| Q38402903 | Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry |
| Q33398742 | Drugs that inhibit complement |
| Q39718845 | Early treatment with eculizumab in atypical haemolytic uraemic syndrome |
| Q57652351 | Eculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature |
| Q44109055 | Eculizumab for paroxysmal nocturnal haemoglobinuria |
| Q24193045 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q24201126 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q37993121 | Eculizumab for treatment of asthma |
| Q33418797 | Eculizumab hepatotoxicity in pediatric aHUS. |
| Q81520078 | Eculizumab in paroxysmal nocturnal haemoglobinuria |
| Q91620656 | Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis |
| Q33404676 | Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation |
| Q26740877 | Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations |
| Q37810103 | Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria |
| Q50648020 | Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. |
| Q50516657 | Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria. |
| Q37956407 | Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria |
| Q48137037 | Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. |
| Q48078070 | Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria |
| Q42377779 | Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort |
| Q37507978 | Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes |
| Q33800427 | Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab |
| Q90390392 | Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
| Q64262934 | Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria |
| Q33425335 | Flow cytometry screening for paroxysmal nocturnal hemoglobinuria: A single-center experience in Saudi Arabia |
| Q37260210 | Ganglioside antibodies and neuropathies |
| Q47688118 | Generation of induced pluripotent stem cells as a potential source of hematopoietic stem cells for transplant in PNH patients. |
| Q54955566 | Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. |
| Q83231513 | Glycosylphosphatidylinositol biosynthesis and remodeling are required for neural tube closure, heart development, and cranial neural crest cell survival |
| Q45340511 | Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. |
| Q38261555 | Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations |
| Q55280532 | Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. |
| Q50918411 | Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? |
| Q24648538 | How I treat paroxysmal nocturnal hemoglobinuria |
| Q33397450 | Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy |
| Q28972502 | Implication of Complement System and its Regulators in Alzheimer’s Disease |
| Q52840713 | Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab. |
| Q48114152 | Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation |
| Q35155748 | Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. |
| Q33410671 | Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection |
| Q26752716 | Inflammogenesis of Secondary Spinal Cord Injury |
| Q24609286 | Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy |
| Q39554119 | Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan |
| Q51834131 | Investigational drugs in systemic vasculitis. |
| Q33429572 | Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab |
| Q38170629 | Learnings from over 25 years of PNH experience: the era of targeted complement inhibition |
| Q50209347 | Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature |
| Q44681539 | Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial |
| Q33439129 | Long-term remission with eculizumab in atypical haemolytic uraemic syndrome |
| Q37098212 | Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria |
| Q42783308 | Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria |
| Q38927860 | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
| Q37868639 | Management of paroxysmal nocturnal haemoglobinuria: a personal view. |
| Q37638781 | Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide |
| Q37955206 | Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q33421884 | Modified Ham test for atypical hemolytic uremic syndrome |
| Q38546571 | Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. |
| Q35061800 | Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia |
| Q35992349 | Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria |
| Q35889067 | Neuronal death in Alzheimer's disease and therapeutic opportunities. |
| Q41430132 | Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab |
| Q38544280 | New anti-complement drugs: not so far away |
| Q42122036 | New drugs approved in 2007. |
| Q90696527 | No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab |
| Q35835471 | PNH is a debilitating, fatal but treatable disease: same disease, different clinical presentations. |
| Q47870686 | Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients |
| Q88093383 | Paroxysmal nocturnal haemoglobinuria |
| Q43441251 | Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test |
| Q34431429 | Paroxysmal nocturnal hemoglobinuria |
| Q42832542 | Paroxysmal nocturnal hemoglobinuria and eculizumab |
| Q38156229 | Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition |
| Q24599629 | Paroxysmal nocturnal hemoglobinuria from bench to bedside |
| Q59135381 | Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice—frequency and indications |
| Q36416292 | Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia |
| Q42036462 | Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents |
| Q38370916 | Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. |
| Q37670073 | Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria |
| Q48152299 | Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants |
| Q27021868 | Pesg PNH diagnosis, follow-up and treatment guidelines |
| Q53132129 | Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. |
| Q24622189 | Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome |
| Q36509944 | Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. |
| Q33403710 | Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria |
| Q38726547 | Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review |
| Q38658582 | Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry |
| Q36751227 | Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience |
| Q54255446 | Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. |
| Q91655288 | Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles |
| Q58780185 | Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies |
| Q61797730 | Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study |
| Q61797732 | Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study |
| Q90170407 | Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
| Q43075185 | Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria |
| Q34907163 | Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases |
| Q33647738 | Review: Complement and its regulatory proteins in kidney diseases |
| Q33422169 | Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome |
| Q34626253 | Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial |
| Q36563619 | Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. |
| Q49282674 | Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria |
| Q33436512 | Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome |
| Q42765070 | Stem cell transplantation for paroxysmal nocturnal hemoglobinuria |
| Q84959423 | Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria |
| Q38086087 | Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era. |
| Q64964418 | Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. |
| Q47333777 | Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery |
| Q36401237 | Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. |
| Q64039708 | The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? |
| Q99571087 | The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies |
| Q27021748 | The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review |
| Q92915955 | The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q33414227 | The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome |
| Q37462959 | The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab |
| Q38828458 | The role of complement activation in thrombosis and hemolytic anemias |
| Q34501102 | The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria |
| Q36698228 | Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE. |
| Q40560617 | Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. |
| Q48468958 | Thrombosis and severe asthenia as priority manifestations in paroxysmal nocturnal haemoglobinuria |
| Q84140432 | Thrombosis in Paroxysmal Nocturnal Hemoglobinuria - insights into the role of complement in thrombosis |
| Q26853483 | Thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q37082416 | Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report |
| Q37924893 | Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab |
| Q94465045 | Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient |
| Q38363645 | Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease |
| Q39027745 | Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. |
| Q38769922 | Use of polyclonal/monoclonal antibody therapies in transplantation |
| Q48568936 | Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease |
Search more.